| Valerie A Caton, FNP | |
|
2223 Mission Way, Billings, MT 59102-0160 | |
| (406) 237-8282 | |
| Not Available |
| Full Name | Valerie A Caton |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 2223 Mission Way, Billings, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104846658 | NPI | - | NPPES |
| 1104846658 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 25407 (Montana) | Secondary |
| 363L00000X | Nurse Practitioner | RN25407 (Montana) | Secondary |
| 363L00000X | Nurse Practitioner | 100370 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Valerie A Caton, FNP 2223 Mission Way, Billings, MT 59102-0160 Ph: (406) 237-8282 | Valerie A Caton, FNP 2223 Mission Way, Billings, MT 59102-0160 Ph: (406) 237-8282 |
News Archive
IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.
The field of microbiology, the study of minute organisms such as bacteria, viruses, archaea, and eukaryotes, is yielding startling new findings about their effects on people and the environment. Keeping current with these advances while keeping up with a demanding workflow can be challenging.
Ex-prisoners with common psychiatric disorders such as bipolar disorder (manic-depressive disorder) and alcohol and drug abuse are substantially more likely to commit a violent crime after release than other prisoners, according to new research published in The Lancet Psychiatry journal.
Women are more sensitive to the effects of cocaine and more susceptible to cocaine abuse than men. Cocaine's ability to disrupt a woman's estrus cycle may explain the sex differences in cocaine addiction, and new evidence that caffeine may be neuroprotective and able to block cocaine's direct effects on the estrus cycle reveals novel treatment possibilities, according to an article published in Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
› Verified 6 days ago